Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
In order to improve the clinical result of high-dose chemotherapy and autologous stem cell
transplantation for B-cell non-Hodgkin's lymphoma, Zevalin will be added to the conditioning
regimen. Investigators expect this radioimmunotherapy of Zevalin plus busulfan,
cyclophosphamide and etoposide regimen will improve survival of relapsed or poor-risk B-cell
non-Hodgkin's lymphoma.